Recent Updates
Recently added Catalysts
PRLD Positive Sentiment Score: 70/100

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Tuesday, August 29, 2023 1 min read
Key Takeaway: Prelude Therapeutics announced its participation in three upcoming healthcare investment conferences in September. Key executives, including CEO Dr. Kris Vaddi and CMO Dr. Jane Huang, will lead discussions and host one-on-one meetings with investors at these events. Their engagements are expected to enhance the company's visibility in the precision oncology sector and promote its diverse pipeline of promising drug candidates.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple respected healthcare investment conferences indicates strong investor interest.
  • Engagement of key executives in live discussions may enhance company visibility and credibility.
  • Showcases the potential of Prelude's innovative drug candidates and clinical pipeline.

Full Press Release Details

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows:
Wells Fargo 18 th Annual Healthcare Conference Boston
Kris Vaddi, Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6, at 4:30 p.m. ET. The live webcast is available here . Dr. Vaddi and Laurent Chardonnet, Chief Financial Officer of Prelude , will host one-on-one meetings at the conference.
H. C. Wainwright 25 th Annual Healthcare Investment Conference
Dr. Vaddi and Jane Huang, MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11, at 1:30 p.m. ET. The live webcast is available here . Dr. Vaddi, along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference.
Morgan Stanley 21 st Annual Global Healthcare Conference
On Tuesday, September 12, at 4:55 p.m. ET, Dr. Vaddi and Dr. Huang will participate in a Fireside chat. The live webcast is available here . Dr. Vaddi, Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference.
About Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor, PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2.
Vice President, Investor Relations
ltrickett@preludetx.com
helen@shikcommunications.com

Tags

Prelude Therapeutics
Healthcare Conference

Frequently Asked Questions

What conferences will Prelude Therapeutics attend?

Prelude Therapeutics will participate in three healthcare investment conferences.

When is the Wells Fargo Healthcare Conference?

The Wells Fargo Healthcare Conference is on September 6 at 4:30 p.m. ET.

Who are the speakers at the H. C. Wainwright Conference?

Dr. Vaddi and Dr. Huang will speak at the H. C. Wainwright Conference.

What is unique about Prelude's drug candidates?

Prelude's candidates target specific cancer pathways with potentially best-in-class properties.

How can investors meet Prelude executives?

Investors can schedule one-on-one meetings with Prelude executives at each conference.

Tags: PRLD Viatris Investor Conferences Healthcare Prelude Therapeutics precision oncology healthcare conferences investor engagement
Last updated: Aug 29, 2023